Sara Valpione 🌻
@saravalpione.bsky.social
Clinical Senior Lecturer, Clinician in Residence, Med Oncology Consultant at Univ. of Manchester & CRUK NBC & Christie; #ESMO UpperGI faculty, #EORTC UGI MRD. #Tcells, #liquid_biopsies, #nanomedicine, #immunotherapy.
Reposted by Sara Valpione 🌻
Excited to share our new study, the paper is out today @cp-immunity.bsky.social! Not all Treg cells are the same. We identified two Treg cell subsets with opposing functions in colorectal cancer (CRC). 1/8
Online now: Opposing functions of distinct regulatory T cell subsets in colorectal cancer
Opposing functions of distinct regulatory T cell subsets in colorectal cancer
Huang et al. study the heterogeneity of regulatory T (Treg) cells in a genetic model of colorectal cancer (CRC) and find that interleukin (IL)-10− Treg cells promote tumor progression, whereas IL-10+ Treg cells restrain tumor growth by suppressing IL-17 production from CD4+ T cells. This functional dichotomy between Treg subsets is seen in human CRC and may be relevant in other barrier tissue cancers.
dlvr.it
December 15, 2025 at 9:34 PM
Excited to share our new study, the paper is out today @cp-immunity.bsky.social! Not all Treg cells are the same. We identified two Treg cell subsets with opposing functions in colorectal cancer (CRC). 1/8
Reposted by Sara Valpione 🌻
Branched Chain Amino Acids identified as an immune priming factor, a potential mechanism underlying the well-established association between circulating BCAA and diverse diseases of #aging #inflammation www.sciencedirect.com/science/arti...
Branched chain amino acids prime metabolic inflammation
Sterile inflammation is associated with a broad range of metabolic stressors including both dietary excess and prolonged fasting. In a 10-day human fa…
www.sciencedirect.com
December 15, 2025 at 8:44 PM
Branched Chain Amino Acids identified as an immune priming factor, a potential mechanism underlying the well-established association between circulating BCAA and diverse diseases of #aging #inflammation www.sciencedirect.com/science/arti...
Reposted by Sara Valpione 🌻
📢 Telomere community: Registration and abstract submission are now open for the EMBO Workshop “Telomere function and maintenance in health and disease”, May 25–30, 2026, in Lazise, Italy 🇮🇹. Looking forward to an exciting meeting! Please re-post. meetings.embo.org/event/26-tel...
Telomere function and maintenance in health and disease
Telomeres are specialized structures that protect the ends of linear chromosomes in eukaryotes. Research in this area has revealed that telomere maintenance is critical for stem cell function and nor…
meetings.embo.org
December 15, 2025 at 5:57 PM
📢 Telomere community: Registration and abstract submission are now open for the EMBO Workshop “Telomere function and maintenance in health and disease”, May 25–30, 2026, in Lazise, Italy 🇮🇹. Looking forward to an exciting meeting! Please re-post. meetings.embo.org/event/26-tel...
Reposted by Sara Valpione 🌻
Can one map the genome-wide binding (1) and its protein partners (2) simultaneously from the same sample?
Yes, one can. with CUT&ID ✂️🪪
Spearheaded — singlehandedly — by @annanordin.bsky.social
No need of transgenesis, cloning and overexpression.
Check it out, it's fast and its works.
Yes, one can. with CUT&ID ✂️🪪
Spearheaded — singlehandedly — by @annanordin.bsky.social
No need of transgenesis, cloning and overexpression.
Check it out, it's fast and its works.
December 13, 2025 at 7:00 AM
Can one map the genome-wide binding (1) and its protein partners (2) simultaneously from the same sample?
Yes, one can. with CUT&ID ✂️🪪
Spearheaded — singlehandedly — by @annanordin.bsky.social
No need of transgenesis, cloning and overexpression.
Check it out, it's fast and its works.
Yes, one can. with CUT&ID ✂️🪪
Spearheaded — singlehandedly — by @annanordin.bsky.social
No need of transgenesis, cloning and overexpression.
Check it out, it's fast and its works.
Reposted by Sara Valpione 🌻
Happy to see our News & Views is out! We highlight two landmark papers demonstrating the potential for therapeutic targeting of FSP1 and #ferroptosis in in vivo cancer models. Beautiful work from @ubellackerlab.bsky.social, Thales Papagiannakopoulos, and colleagues. 🥳
www.nature.com/articles/s41...
www.nature.com/articles/s41...
In vivo models bring FSP1 inhibitors to life - Nature Cell Biology
FSP1 is a key suppressor of lipid peroxidation and ferroptosis, yet it is largely dispensable in standard cell culture models. Two new studies now show that FSP1 becomes essential for tumour growth in...
www.nature.com
December 12, 2025 at 4:15 PM
Happy to see our News & Views is out! We highlight two landmark papers demonstrating the potential for therapeutic targeting of FSP1 and #ferroptosis in in vivo cancer models. Beautiful work from @ubellackerlab.bsky.social, Thales Papagiannakopoulos, and colleagues. 🥳
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Sara Valpione 🌻
The dark proteome: translation from noncanonical open reading frames
1⃣5'-UTR 2⃣3'-UTR small ORF/sORF
3⃣out-of-frame 4⃣In-frame overlapping ORF
Translating micropeptide <100aa, proteins distinct from canonical ORFs, or isoforms
#TrendsCellBio 2022
www.sciencedirect.com/science/arti...
1⃣5'-UTR 2⃣3'-UTR small ORF/sORF
3⃣out-of-frame 4⃣In-frame overlapping ORF
Translating micropeptide <100aa, proteins distinct from canonical ORFs, or isoforms
#TrendsCellBio 2022
www.sciencedirect.com/science/arti...
December 13, 2025 at 1:34 PM
The dark proteome: translation from noncanonical open reading frames
1⃣5'-UTR 2⃣3'-UTR small ORF/sORF
3⃣out-of-frame 4⃣In-frame overlapping ORF
Translating micropeptide <100aa, proteins distinct from canonical ORFs, or isoforms
#TrendsCellBio 2022
www.sciencedirect.com/science/arti...
1⃣5'-UTR 2⃣3'-UTR small ORF/sORF
3⃣out-of-frame 4⃣In-frame overlapping ORF
Translating micropeptide <100aa, proteins distinct from canonical ORFs, or isoforms
#TrendsCellBio 2022
www.sciencedirect.com/science/arti...
Reposted by Sara Valpione 🌻
There are a lot of ways to be 💩in this world; the work of clinician-scientists is one of the best ways to still get to act with honor
(This one goes out to those of you working this Friday night in house. Thanks for keeping our patients safe)
(This one goes out to those of you working this Friday night in house. Thanks for keeping our patients safe)
December 13, 2025 at 1:30 AM
There are a lot of ways to be 💩in this world; the work of clinician-scientists is one of the best ways to still get to act with honor
(This one goes out to those of you working this Friday night in house. Thanks for keeping our patients safe)
(This one goes out to those of you working this Friday night in house. Thanks for keeping our patients safe)
Reposted by Sara Valpione 🌻
An excellent opportunity for summer undergraduate research - the Cech Fellows Program! Applications due in 10 days:
www.hhmi.org/programs/cec...
www.hhmi.org/programs/cec...
Summer Undergraduate Research Experience (REU) | Cech Fellows | HHMI
The Cech Fellows Program is a paid, nine-week summer research experience empowering the next generation of scientific leaders.
www.hhmi.org
December 12, 2025 at 9:47 PM
An excellent opportunity for summer undergraduate research - the Cech Fellows Program! Applications due in 10 days:
www.hhmi.org/programs/cec...
www.hhmi.org/programs/cec...
Reposted by Sara Valpione 🌻
Big news for a #SmokefreeUK! @senedd.wales has voted for the Tobacco & Vapes Bill, which aims to help end cancers caused by smoking and create the first smokefree generation. We now want to see the Bill passed in @houseoflords.parliament.uk and implemented across all four nations.
December 10, 2025 at 12:15 PM
Big news for a #SmokefreeUK! @senedd.wales has voted for the Tobacco & Vapes Bill, which aims to help end cancers caused by smoking and create the first smokefree generation. We now want to see the Bill passed in @houseoflords.parliament.uk and implemented across all four nations.
Reposted by Sara Valpione 🌻
Reposted by Sara Valpione 🌻
📢 Don’t miss the last Cancer Biology and Medicine talk of 2025 tomorrow!
Cancer immunology and immunotherapy
Prof Rahul Roychoudhuri @campathology.bsky.social
📅 Thurs 11 December, 9:30-10:30
📍Theo Chalmers lecture theatre, School of Clinical Medicine
All welcome! @cambridge-scm.bsky.social
Cancer immunology and immunotherapy
Prof Rahul Roychoudhuri @campathology.bsky.social
📅 Thurs 11 December, 9:30-10:30
📍Theo Chalmers lecture theatre, School of Clinical Medicine
All welcome! @cambridge-scm.bsky.social
December 10, 2025 at 10:00 AM
📢 Don’t miss the last Cancer Biology and Medicine talk of 2025 tomorrow!
Cancer immunology and immunotherapy
Prof Rahul Roychoudhuri @campathology.bsky.social
📅 Thurs 11 December, 9:30-10:30
📍Theo Chalmers lecture theatre, School of Clinical Medicine
All welcome! @cambridge-scm.bsky.social
Cancer immunology and immunotherapy
Prof Rahul Roychoudhuri @campathology.bsky.social
📅 Thurs 11 December, 9:30-10:30
📍Theo Chalmers lecture theatre, School of Clinical Medicine
All welcome! @cambridge-scm.bsky.social
Reposted by Sara Valpione 🌻
In patients with HER2-positive early breast cancer and residual disease after neoadjuvant therapy, trastuzumab deruxtecan improved invasive disease–free survival but carried a risk of interstitial lung disease. Full DESTINY-Breast05 phase 3 trial results: nej.md/4an3Az2
December 10, 2025 at 7:05 PM
In patients with HER2-positive early breast cancer and residual disease after neoadjuvant therapy, trastuzumab deruxtecan improved invasive disease–free survival but carried a risk of interstitial lung disease. Full DESTINY-Breast05 phase 3 trial results: nej.md/4an3Az2
Reposted by Sara Valpione 🌻
Reposted by Sara Valpione 🌻
Our Director, Prof Tracy Hussell @tracyh9494.bsky.social has been shortlisted for a prestigious @nature.com Award for Mentoring in the Life Time Achievement category!
🤞Everyone at the Becker wishes Tracy the best of luck at this evening's Awards Ceremony.
www.nature.com/nature/award...
🤞Everyone at the Becker wishes Tracy the best of luck at this evening's Awards Ceremony.
www.nature.com/nature/award...
Mentoring | Nature
Mentoring
www.nature.com
December 9, 2025 at 4:46 PM
Our Director, Prof Tracy Hussell @tracyh9494.bsky.social has been shortlisted for a prestigious @nature.com Award for Mentoring in the Life Time Achievement category!
🤞Everyone at the Becker wishes Tracy the best of luck at this evening's Awards Ceremony.
www.nature.com/nature/award...
🤞Everyone at the Becker wishes Tracy the best of luck at this evening's Awards Ceremony.
www.nature.com/nature/award...
Reposted by Sara Valpione 🌻
Highly recommend this piece from @lizziegadd.bsky.social and @bedforms.bsky.social on the new report on #GenerativeAI and #REF2029
wonkhe.com/blogs/before...
"The challenge, now, is to ensure that its integration reflects sector values, not just technological possibility."
wonkhe.com/blogs/before...
"The challenge, now, is to ensure that its integration reflects sector values, not just technological possibility."
Before we automate REF there are three issues we need to talk about
Lizzie Gadd and Dan Parsons argue that if AI is to be embedded into REF it should reflect sector values not just technological possibility
wonkhe.com
December 9, 2025 at 4:57 PM
Highly recommend this piece from @lizziegadd.bsky.social and @bedforms.bsky.social on the new report on #GenerativeAI and #REF2029
wonkhe.com/blogs/before...
"The challenge, now, is to ensure that its integration reflects sector values, not just technological possibility."
wonkhe.com/blogs/before...
"The challenge, now, is to ensure that its integration reflects sector values, not just technological possibility."
Reposted by Sara Valpione 🌻
In relapsed or refractory multiple myeloma, teclistamab plus daratumumab significantly prolonged progression-free survival as compared with DPd or DVd (83.4% vs. 29.7%) and had higher response rates. Full MajesTEC-3 phase 3 trial results: nej.md/4431DUD
#SABCS25 | @sabcs.bsky.social
#SABCS25 | @sabcs.bsky.social
December 9, 2025 at 12:37 PM
In relapsed or refractory multiple myeloma, teclistamab plus daratumumab significantly prolonged progression-free survival as compared with DPd or DVd (83.4% vs. 29.7%) and had higher response rates. Full MajesTEC-3 phase 3 trial results: nej.md/4431DUD
#SABCS25 | @sabcs.bsky.social
#SABCS25 | @sabcs.bsky.social
Reposted by Sara Valpione 🌻
Looking good! @salient-hub.bsky.social 🎄
How's everyone getting their offices into the festive spirit?🎅
How's everyone getting their offices into the festive spirit?🎅
December 9, 2025 at 5:14 PM
Looking good! @salient-hub.bsky.social 🎄
How's everyone getting their offices into the festive spirit?🎅
How's everyone getting their offices into the festive spirit?🎅
Reposted by Sara Valpione 🌻
President of the Royal Society Sir Paul Nurse has spoken out on the challenges currently facing science, criticising those who put ideology ahead of evidence and called for smarter funding of UK science: https://royalsociety.org/news/2025/12/new-president-speaks-out-on-challenges-to-science/
New President speaks out on challenges to science | Royal Society
Paul Nurse, the new President of the Royal Society has criticised those who put ideology ahead of evidence and called for smarter funding of UK science.
royalsociety.org
December 9, 2025 at 5:29 PM
President of the Royal Society Sir Paul Nurse has spoken out on the challenges currently facing science, criticising those who put ideology ahead of evidence and called for smarter funding of UK science: https://royalsociety.org/news/2025/12/new-president-speaks-out-on-challenges-to-science/
Reposted by Sara Valpione 🌻
Dr. Quynh Long Khuong from UPenn presents on possible use of BB/ACEi to reduce cardiotoxicity in pediatric pts w/ AML receiving anthracycline-based induction using multicenter cohort. 908 pts studied; modest but significant reduction in LVEF reduction and mortality w/ BB. (1/2) #ASH25
December 8, 2025 at 9:10 PM
Dr. Quynh Long Khuong from UPenn presents on possible use of BB/ACEi to reduce cardiotoxicity in pediatric pts w/ AML receiving anthracycline-based induction using multicenter cohort. 908 pts studied; modest but significant reduction in LVEF reduction and mortality w/ BB. (1/2) #ASH25
Reposted by Sara Valpione 🌻
Targeting CREB remodels the immune microenvironment to enhance immunotherapy responses in pancreatic cancer https://www.biorxiv.org/content/10.64898/2025.12.04.691935v1
December 9, 2025 at 3:49 AM
Targeting CREB remodels the immune microenvironment to enhance immunotherapy responses in pancreatic cancer https://www.biorxiv.org/content/10.64898/2025.12.04.691935v1
Reposted by Sara Valpione 🌻
Reposted by Sara Valpione 🌻
Our recent manuscript in @aacrjournals.bsky.social Cancer Discovery! Can a high fiber diet delay progression to myeloma?
doi.org/10.1158/2159...
#ASH25 #mmsm
doi.org/10.1158/2159...
#ASH25 #mmsm
Now in Cancer Discovery @aacrjournals.bsky.social: A High-Fiber Plant-Based Diet in Myeloma Precursor Disorders – Results from the NUTRIVENTION Clinical Trial & Preclinical Vk*MYC Model doi.org/10.1158/2159...
December 6, 2025 at 3:53 AM
Our recent manuscript in @aacrjournals.bsky.social Cancer Discovery! Can a high fiber diet delay progression to myeloma?
doi.org/10.1158/2159...
#ASH25 #mmsm
doi.org/10.1158/2159...
#ASH25 #mmsm
Reposted by Sara Valpione 🌻
VALIANT phase 3 trial: Treatments are needed for C3 glomerulopathy & primary immune-complex membranoproliferative glomerulonephritis. Pegcetacoplan, a targeted C3 & C3b inhibitor, showed promise in phase 2 trials. Research findings are summarized in a new Quick Take video. nej.md/4rNHo7E
December 8, 2025 at 5:01 PM
VALIANT phase 3 trial: Treatments are needed for C3 glomerulopathy & primary immune-complex membranoproliferative glomerulonephritis. Pegcetacoplan, a targeted C3 & C3b inhibitor, showed promise in phase 2 trials. Research findings are summarized in a new Quick Take video. nej.md/4rNHo7E
Reposted by Sara Valpione 🌻
Really excited to see this new paper from our friends & neighbors in the other Pietras lab @kpietraslab.bsky.social, uncovering surprising (?) roles of pericytes in the GBM microenvironment. Congrats all, and thanks for including us! www.nature.com/articles/s41...
Pericytes orchestrate a tumor-restraining microenvironment in glioblastoma - Nature Communications
Improved understanding of the tumor ecosystem in glioblastoma is critical for developing new treatment strategies for the disease. Here, the authors identify pericytes as an active paracrine signaling...
www.nature.com
December 5, 2025 at 3:14 PM
Really excited to see this new paper from our friends & neighbors in the other Pietras lab @kpietraslab.bsky.social, uncovering surprising (?) roles of pericytes in the GBM microenvironment. Congrats all, and thanks for including us! www.nature.com/articles/s41...
Reposted by Sara Valpione 🌻
Excited to share the first December issue of bims-metlip featuring the latest advancements in small molecule analysis.
biomed.news/bims-metlip/...
A collaboration with @biomednews.bsky.social
#SmallMoleculeAnalysis #Metabolomics #Lipidomics
biomed.news/bims-metlip/...
A collaboration with @biomednews.bsky.social
#SmallMoleculeAnalysis #Metabolomics #Lipidomics
a cartoon raccoon is writing on a piece of paper with a pencil
ALT: a cartoon raccoon is writing on a piece of paper with a pencil
media.tenor.com
December 7, 2025 at 6:19 PM
Excited to share the first December issue of bims-metlip featuring the latest advancements in small molecule analysis.
biomed.news/bims-metlip/...
A collaboration with @biomednews.bsky.social
#SmallMoleculeAnalysis #Metabolomics #Lipidomics
biomed.news/bims-metlip/...
A collaboration with @biomednews.bsky.social
#SmallMoleculeAnalysis #Metabolomics #Lipidomics